---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-25-000018"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:15:39.006000+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M

## Summary
- Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.
- AVISE CTD trailing 12-mo ASP reached $411, a $75 increase per test.
- FY net loss improved ~$8M YoY to ($15.1M); adjusted EBITDA loss improved ~$7M to ($10.1M).
- Surpassed 1 million patients tested with AVISE CTD; launched new SLE and RA biomarker assays in Jan 2025.
- Expects positive adjusted EBITDA in Q4 2025; Q1 2025 revenue at least $14.5M.

## SEC filing metadata
- accession: 0001274737-25-000018
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473725000018/0001274737-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473725000018/exdx-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-25-000018
- JSON: https://secwatch.observer/filing/0001274737-25-000018.json
- Plain text: https://secwatch.observer/filing/0001274737-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.